Evidence map›Paper›PMID 35173208›Full record

ArticleScientific reports2022

Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition.

Jiri Jungwirth, Marketa Urbanova, Arnoud Boot, Petr Hosek, Petra Bendova, Anna Siskova, Jiri Svec, Milan Kment, Daniela Tumova, Sandra Summerova and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jiri Jungwirth *Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Marketa Urbanova *Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Arnoud BootDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Petr HosekBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.
Petra BendovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Anna SiskovaInstitute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Jiri SvecInstitute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic.
Milan KmentSecond Department of Internal Medicine, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34, Prague 10, Czech Republic.
Daniela TumovaDT Gastroenterology, Roskotova 1/1225, Prague 4, Czech Republic.
Sandra SummerovaDepartment of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.
Zdenek BenesDepartment of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.
Tomas BuchlerDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
Pavel KohoutDepartment of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.
Tomas HuclDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21, Prague, Czech Republic.
Radoslav MatejDepartment of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
Ludmila VodickovaInstitute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Tom van WezelDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Pavel VodickaInstitute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Veronika VymetalkovaInstitute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic. veronika.vymetalkova@iem.cas.cz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma-high-grade adenomas-in situ carcinoma: APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.

Indexed as

Microsatellite InstabilityMutationAdenomaAgedBiomarkers, TumorCarcinoma in SituColorectal NeoplasmsDNA MethylationFemaleFollow-Up StudiesHumansMalePrognosisBiomarkers, Tumor

Identifiers

PMID35173208
PMCPMC8850440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.